Clinical Trial

A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)

Study acronym: LIDS
Active, Not Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
The overall objective is to study the safety, pharmacokinetics and efficacy of linsitinib (a small molecule IGF-1R inhibitor) administered orally twice daily (BID) vs. placebo, at 24 weeks in the treatment of subjects with active, moderate to severe thyroid eye disease (TED).
Protocol Amendment History 20 amendments
This ClinicalTrials.gov record has been amended 20 times since 2022-03-02; most recent amendment 2025-01-27.
Status change: Recruiting → Active, Not Recruiting 2024-05-29
Status change: Not Yet Recruiting → Recruiting 2022-07-21
Trial Details
NCT Number NCT05276063
Lead Sponsor Sling Therapeutics, Inc.
Conditions Thyroid Eye Disease, Graves Orbitopathy, Endocrine System Diseases, Eye Diseases, Thyroid Associated Ophthalmopathy, Graves Ophthalmopathy, Thyroid Diseases, Orbital Diseases +4 more
Enrollment 90 participants
Start Date 2022-07-01
Primary Completion 2024-10-15 (estimated)
Study Completion 2026-09 (estimated)
Updated on ClinicalTrials.gov 2025-01-29